Application of Rivaroxaban in the Prevention of Deep Vein Thrombosis before and after Total Hip Replacement

Objective: To explore the effects and advantages of rivaroxaban in the prevention of deep vein thrombosis before and after total hip replacement by comparing it with the low molecular weight heparin group and control group.Methods: By a retrospective of 224 cases of total hip replacement from May,2009 to May,2012,to randomly divide them into Group A rivaroxaban and group B low molecular weight heparin(Clexane),and the group C(control group) for comparison.Result: The patients in Group A with deep vein thrombosis was significantly less than that in group B(P 0.05) and C,without significantly increase of the risk of bleeding and other adverse reactions.Conclusion: For deep vein thrombosis prophylactic treatment during total hip replacement perioperative,rivaroxaban is better than either the low molecular weight heparin or control group,accompanied with lower risk of untoward reaction.